Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone011-353-1268-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.95 billion
Profitability
Miscellaneous
Employees2,910
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Endo International (NASDAQ:ENDP) Frequently Asked Questions
What is Endo International's stock symbol?
Endo International trades on the NASDAQ under the ticker symbol "ENDP."
How were Endo International's earnings last quarter?
Endo International PLC (NASDAQ:ENDP) announced its quarterly earnings data on Thursday, May, 9th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.11. The business had revenue of $720 million for the quarter, compared to analysts' expectations of $692.31 million. Endo International had a negative return on equity of 199.18% and a negative net margin of 18.35%. The company's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the firm earned $0.67 earnings per share. View Endo International's Earnings History.
When is Endo International's next earnings date?
What guidance has Endo International issued on next quarter's earnings?
Endo International updated its FY19 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of $2.00-2.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.17. The company issued revenue guidance of $2.76-2.96 billion, compared to the consensus revenue estimate of $2.87 billion.Endo International also updated its FY 2019 guidance to $2.00-2.25 EPS.
What price target have analysts set for ENDP?
19 analysts have issued 1-year price objectives for Endo International's shares. Their predictions range from $4.75 to $26.00. On average, they anticipate Endo International's share price to reach $12.8594 in the next twelve months. This suggests a possible upside of 223.9% from the stock's current price. View Analyst Price Targets for Endo International.
What is the consensus analysts' recommendation for Endo International?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 1 sell rating, 13 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endo International.
Has Endo International been receiving favorable news coverage?
News coverage about ENDP stock has been trending somewhat negative on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Endo International earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Endo International.
Are investors shorting Endo International?
Endo International saw a increase in short interest in May. As of May 15th, there was short interest totalling 22,204,400 shares, an increase of 11.3% from the April 15th total of 19,949,300 shares. Based on an average daily trading volume, of 3,590,000 shares, the short-interest ratio is currently 6.2 days. Currently, 10.9% of the shares of the stock are sold short. View Endo International's Current Options Chain.
Who are some of Endo International's key competitors?
Some companies that are related to Endo International include Ultragenyx Pharmaceutical (RARE), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Uniqure (QURE), Agios Pharmaceuticals (AGIO), Arena Pharmaceuticals (ARNA), Amicus Therapeutics (FOLD), The Medicines (MDCO), Reata Pharmaceuticals (RETA), Biohaven Pharmaceutical (BHVN), Arrowhead Pharmaceuticals (ARWR), PTC Therapeutics (PTCT) and Intercept Pharmaceuticals (ICPT).
What other stocks do shareholders of Endo International own?
Who are Endo International's key executives?
Endo International's management team includes the folowing people:
- Mr. Paul V. Campanelli, Pres, CEO & Director (Age 57)
- Mr. Blaise Coleman, Exec. VP & CFO (Age 45)
- Mr. Terrance J. Coughlin, Exec. VP & COO (Age 53)
- Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 47)
- Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 62)
Who are Endo International's major shareholders?
Endo International's stock is owned by many different of institutional and retail investors. Top institutional investors include Connor Clark & Lunn Investment Management Ltd. (0.84%), Diamond Hill Capital Management Inc. (0.60%), Acadian Asset Management LLC (0.34%), Rhumbline Advisers (0.23%), New York State Teachers Retirement System (0.15%) and Globeflex Capital L P (0.09%). Company insiders that own Endo International stock include Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel, Terrance J Coughlin and William P Montague. View Institutional Ownership Trends for Endo International.
Which institutional investors are selling Endo International stock?
ENDP stock was sold by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc., Gabelli Funds LLC, O Shaughnessy Asset Management LLC, American International Group Inc., Globeflex Capital L P, New York State Teachers Retirement System and Systematic Financial Management LP. Company insiders that have sold Endo International company stock in the last year include Nancy J Hutson, Roger H Kimmel and William P Montague. View Insider Buying and Selling for Endo International.
Which institutional investors are buying Endo International stock?
ENDP stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Connor Clark & Lunn Investment Management Ltd., Tibra Equities Europe Ltd, Nordea Investment Management AB, BNP Paribas Arbitrage SA, Diamond Hill Capital Management Inc., Factorial Partners LLC and Signition LP. Company insiders that have bought Endo International stock in the last two years include Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli and Terrance J Coughlin. View Insider Buying and Selling for Endo International.
How do I buy shares of Endo International?
Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Endo International's stock price today?
One share of ENDP stock can currently be purchased for approximately $3.97.
How big of a company is Endo International?
Endo International has a market capitalization of $897.94 million and generates $2.95 billion in revenue each year. The company earns $-1,031,470,000.00 in net income (profit) each year or $2.89 on an earnings per share basis. Endo International employs 2,910 workers across the globe.View Additional Information About Endo International.
What is Endo International's official website?
How can I contact Endo International?
Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]
MarketBeat Community Rating for Endo International (NASDAQ ENDP)
MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
